Dianthus Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-162.3M | $-85.0M | $-43.6M | $-28.5M | $-71.1M | $-74.9M | $-76.8M | $-57.5M |
| Depreciation & Amortization | — | — | — | $1.9M | $2.0M | $2.0M | $1.8M | $875.0K |
| Depreciation | $111.0K | $96.0K | $67.0K | $30.0K | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $22.8M | $12.9M | $2.9M | $1.5M | $10.3M | $9.9M | $10.0M | $10.7M |
| Net Cash from Operating Activities | $-129.1M | $-78.2M | $-36.9M | $-29.1M | $-59.5M | $-64.0M | $-57.1M | $-41.9M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | $314.0K | $1.3M | $400.0K | $3.1M | $7.7M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-122.8M | $-286.8M | $20.3M | $-59.8M | $43.4M | $-10.6M | $1.5M | $-91.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $280.1M | $255.6M | $133.6M | $96.7M | $89.6M | $67.7M | $62.3M | $142.1M |
| Net Change in Cash | $28.2M | $-109.4M | $117.0M | $7.8M | $73.5M | $-6.9M | $6.7M | $8.6M |
| Free Cash Flow | — | — | — | $-29.4M | $-60.8M | $-64.4M | $-60.2M | $-49.6M |